Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab

Koki Nakashima; Yoshiki Demura; Masahiro Oi; Mio Tabata; Toshihiko Tada; Kohei Shiozaki; Masaya Akai; Tamotsu Ishizuka

doi:10.2169/internalmedicine.5216-20

CASE REPORTS

Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab

Koki Nakashima, Yoshiki Demura, Masahiro Oi, Mio Tabata, Toshihiko Tada, Kohei Shiozaki, Masaya Akai, Tamotsu Ishizuka

Author information

Koki Nakashima
Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan
Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan
Yoshiki Demura
Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan
Masahiro Oi
Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan
Mio Tabata
Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan
Toshihiko Tada
Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan
Kohei Shiozaki
Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan
Masaya Akai
Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan
Tamotsu Ishizuka
Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan

Keywords: non-small-cell lung cancer, immune checkpoint inhibitor, durvalumab, immune-related adverse event, hepatitis, infliximab

JOURNAL OPEN ACCESS

2020 Volume 59 Issue 23 Pages 3055-3059

DOI https://doi.org/10.2169/internalmedicine.5216-20

Browse “Advance online publication” version

Details

Abstract

A 69-year-old man with stage III lung squamous cell carcinoma developed immune-related hepatitis following treatment with durvalumab, and was given high-dose corticosteroids and immunosuppressive drugs (mycophenolate mofetil, azathioprine, tacrolimus) but without demonstrating any improvement. Two cycles of infliximab (5 mg/kg) were then administered and thereafter the hepatitis improved. At the time of writing (9 months after the initiation of first course of durvalumab), the patient is alive without either any hepatitis symptoms nor any lung cancer progression.

Infliximab may be effective for treating non-small cell lung cancer (NSCLC) patients who develop immunosuppressive drug-resistant immune-related hepatitis caused by durvalumab.

Corresponding author

Register with J-STAGE for free!